Biohaven submits NDA to FDA - Ataxia UK

Biohaven submits NDA to FDA

Post Published: June 1, 2023

Biohaven is a pharmaceutical company with an ataxia research programme. They carried out a clinical trial testing Troriluzole in a number of SCAs. Results of this 48 week trial showed that there was a treatment benefit to people with Spinocerebellar ataxia type 3 (SCA3).

Following these positive results for SCA3, Biohaven announced that they have submitted a New Drug Application (NDA) to the regulators in America (the FDA) for the treatment of SCA3.

Read more in their press release here.

Subscribe To Our Newsletter

fundraise image


Take part in a challenge or create your fundraiser. Every penny you raise will help those affected by ataxia.

Donate Image


To make either a one off or recurring donation which will help fund research into treatments and cures and supports those affected ataxia

Volunteer Image


Support the ataxia community and volunteer with Ataxia UK. From social media to telephone befriending, there are loads of ways you can make a difference to someone's life.

Donate Now
Scroll to Top